Company Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus.
Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
| Country | United Kingdom |
| Founded | 1715 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 68,629 |
| CEO | Emma Walmsley |
Contact Details
Address: 79 New Oxford Street London, WC1A 1DG United Kingdom | |
| Phone | 44 20 8047 5000 |
| Website | gsk.com |
Stock Details
| Ticker Symbol | GSK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| CIK Code | 0001131399 |
| CUSIP Number | 37733W204 |
| ISIN Number | US37733W2044 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sally Jackson | Senior Vice President of Global Communications and Chief Executive Officer Office |
| Emma Natasha Walmsley | Chief Executive Officer and Director |
| Julie Belita Brown A.C.A. | Chief Financial Officer and Executive Director |
| Dr. Jesse L. Goodman M.D., M.P.H. | Scientific and Medical Expert |
| Shobie Ramakrishnan | Chief Digital and Technology Officer |
| Tony Wood | Chief Scientific Officer and Head of Research & Development |
| James Ford | Senior Vice President and Group General Counsel of Legal & Compliance |
| David Simon Redfern BSc (Hons), CA | President of Corporate Development |
| Diana Conrad | Chief People Officer |
| Philip C. Thomson | President of Global Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2025 | 6-K | Report of foreign issuer |
| Jun 4, 2025 | 6-K | Report of foreign issuer |
| Jun 4, 2025 | 6-K | Report of foreign issuer |
| Jun 3, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| May 30, 2025 | SD | Form - SD |
| May 30, 2025 | 6-K | Report of foreign issuer |